重组人干扰素联合恩替卡韦治疗慢性乙肝的效果观察

龙源期刊网 https://www.wendangku.net/doc/5a14119683.html,

重组人干扰素联合恩替卡韦治疗慢性乙肝的效果观察

作者：刘丹

来源：《中国实用医药》2018年第08期

【摘要】目的观察分析重组人干扰素联合恩替卡韦治疗慢性乙型肝炎（乙肝）的效果。方法 104例慢性乙肝患者，采用数字随机法分为观察组与对照组，每组52例。对照组患者给予恩替卡韦治疗，观察组患者联合重组人干扰素α-2a与恩替卡韦治疗。对比两组患者的治疗效果。结果观察组患者的治疗总有效率90.38%显著高于对照组的73.08%，差异具有统计学

意义（P0.05）；两组患者治疗6、12、24、48周的ALT、HBV-DNA、HBeAg、HBsAg水平均显著低于治疗前，且观察组均显著低于对照组，差异均具有统计学意义（P

【关键词】慢性乙型肝炎；重组人干扰素α-2a；恩替卡韦

DOI：10.14163/https://www.wendangku.net/doc/5a14119683.html,ki.11-5547/r.2018.08.048

Observation of effect of recombinant human interferon combined with entecavir in the treatment of chronic hepatitis B LIU Dan. Liaoning Fushun Infectious Disease Hospital， Fushun 113000，China

【Abstract】 Objective To observe and analyze the effect of recombinant human interferon combined with entecavir in the treatment of chronic hepatitis B. Methods A total of 104 chronic hepatitis B patients were divided by random number table method into observation group and control group， with 52 cases in each group. The control group was treated with entecavir， and the observation group was treated wi th recombinant human interferon α-2a and entecavir. The treatment effect in two groups was compared. Results The observation group had obviously higher total treatment effective rate as 90.38% than 73.08% in the control group， and the difference was statistically significant （P0.05）. Both groups had significantly lower ALT， HBV-DNA， HBeAg and HBsAg level after 6， 12， 24 and 48 weeks of treatment than before treatment， and the observation group was obviously lower than the control group. Their difference was statistically significant （P

【Key words】 Chronic hepatitis B；Recombinant human interferon α-2a； Entecavir

慢性乙肝是我国常见的一种慢性传染性疾病，乙肝病毒检测为阳性，临床症状主要表现为乏力、畏食、恶心、腹胀、肝区疼痛等，患者肝硬化、肝癌发病率较高，严重威胁着人们的身体健康[1]。目前临床上多采用干扰素及恩替卡韦治疗，但两种药物单用治疗高病毒载量慢性乙肝的疗效不佳，停药后复发率较高[2， 3]。因此，本次采用重组人干扰素α-2a与恩替卡韦联合治疗慢性乙肝，治疗效果满意，现报告如下。